FibroBiologics, Inc. (FBLG)
0.2585
0.00 (0.00%)
USD |
NASDAQ |
Dec 19, 16:00
0.274
+0.02
(+6.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 13.30M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -87.27% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 106.41 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 56.90 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX. |
| URL | http://www.fibrobiologics.com |
| Investor Relations URL | https://ir.fibrobiologics.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX. |
| URL | http://www.fibrobiologics.com |
| Investor Relations URL | https://ir.fibrobiologics.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |